AR117118A1 - Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides - Google Patents

Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides

Info

Publication number
AR117118A1
AR117118A1 ARP190103390A ARP190103390A AR117118A1 AR 117118 A1 AR117118 A1 AR 117118A1 AR P190103390 A ARP190103390 A AR P190103390A AR P190103390 A ARP190103390 A AR P190103390A AR 117118 A1 AR117118 A1 AR 117118A1
Authority
AR
Argentina
Prior art keywords
disease
amino acid
cannabinoid
fatty amino
syndrome
Prior art date
Application number
ARP190103390A
Other languages
English (en)
Inventor
Gregory Wesner
Andrea Leone-Bay
Original Assignee
Receptor Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Holdings Inc filed Critical Receptor Holdings Inc
Publication of AR117118A1 publication Critical patent/AR117118A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un método para preparar una formulación oral de cannabinoides con menor variabilidad de absorción en sangre de cannabinoides en un sujeto que comprende agregar un cannabinoide y una cantidad eficaz de un aminoácido graso N-acilado o una sal de este a una formulación oral. Reivindicación 5: El método de la reivindicación 1, donde la formulación oral comprende 50 mg de cannabidiol (CBD) y 300 mg de aminoácido graso N-acilado o una sal de este; 10 mg de D9-Tetrahidrocannabinol (THC) y 100 mg de aminoácido graso N-acilado o una sal de este; 10 mg de THC y 200 mg de aminoácido graso N-acilado o una sal de este; 50 mg de CBD y 500 mg de aminoácido graso N-acilado o una sal de este; o 30 mg de CBD y 300 mg de aminoácido graso N-acilado o una sal de este. Reivindicación 18: El método de la reivindicación 1, donde el cannabinoide comprende un cannabinoide a base de plantas o un cannabinoide sintético. Reivindicación 19: El método de la reivindicación 1, donde la formulación oral comprende compuestos flavonoides, terpenos, o terpenoides. Reivindicación 21: El método de la reivindicación 1, donde el aminoácido graso N-acilado comprende monosodio-N-saliciloil-8-aminocaprilato, disodio-N-saliciloil-8-aminocaprilato, o ácido N-(saliciloil)-8-aminocaprílico. Reivindicación 22: El método de la reivindicación 1, donde el aminoácido graso N-acilado o sal de este comprende el compuesto de fórmula (1) donde X y Z son independientemente H, un catión monovalente, un catión metálico divalente o un catión orgánico. Reivindicación 38: El método de la reivindicación 1, donde la formulación oral se utiliza para tratar un síntoma de hipotiroidismo adquirido, gastritis aguda, adicción, ADHD, agorafobia, SIDA, anorexia relacionada con SIDA, alcoholismo, enfermedad de Alzheimer, esclerosis lateral amiotrófica (ALS), anquilosis, ansiedad, artritis, síndrome de Asperger, asma, aterosclerosis, autismo, enfermedades autoinmunes, infecciones bacterianas, trastorno bipolar, pérdida ósea, trastornos sanguíneos, lesión cerebral / apoplejía, caquexia, cáncer, síndrome del túnel carpiano, parálisis cerebral, enfermedad de disco cervical, síndrome cervicobraquial, síndrome de fatiga crónica, dolor crónico, cefalea en racimos, conjuntivitis, enfermedad de Crohn, fibrosis quística, depresión, dermatitis, diabetes, distonia, trastornos alimenticios, eccema, epilepsia, fiebre, fibromialgia, gripe, infección fúngica, trastornos gastrointestinales, glaucoma, glioma, enfermedad de Grave, enfermedad cardíaca hepatitis, herpes, enfermedad de Huntington, hipertensión, impotencia, incontinencia, mortalidad infantil, inflamación, enfermedad intestinal inflamatoria (IBD), insomnio, fibrosis hepática, enfermedad de la vaca loca, menopausia, trastornos metabólicos, cefaleas por migraña, mareos por movimiento, MRSA, esclerosis múltiple (MS), distrofia muscular, lesiones de las mucosas, síndrome de nail patella, náuseas y vómitos asociados con quimioterapia para cáncer, neuroinflamación, adicción a la nicotina, obesidad, trastorno obsesivo compulsivo (OCD), dolor, pancreatitis, trastorno del pánico, enfermedad de Parkinson, enfermedad periodontal, neuropatía periférica, dolor del miembro fantasma, alergia a hiedra venenosa, síndrome premenstrual (PMS), miopatía miotónica proximal, trastorno de estrés post-traumático (PTSD), psoriasis, enfermedad de Raynaud, síndrome de piernas inquietas, esquizofrenia, escleroderma, choque séptico, herpes zóster, enfermedad de células falciformes, convulsiones, apnea del sueño, trastornos del sueño, lesiones espinales, estrés, tartamudez, trastorno de la articulación temporomandibular (TMJ), cefaleas por tensión, tinnitus, síndrome de Tourette, recuerdos traumáticos, síndrome consuntivo, y abstinencia.
ARP190103390A 2018-11-19 2019-11-19 Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides AR117118A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862769395P 2018-11-19 2018-11-19

Publications (1)

Publication Number Publication Date
AR117118A1 true AR117118A1 (es) 2021-07-14

Family

ID=70774480

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103390A AR117118A1 (es) 2018-11-19 2019-11-19 Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides

Country Status (9)

Country Link
US (2) US12303487B2 (es)
EP (1) EP3883595A4 (es)
JP (2) JP7566336B2 (es)
AR (1) AR117118A1 (es)
AU (1) AU2019385420A1 (es)
CA (1) CA3120001A1 (es)
MX (1) MX2021005807A (es)
UY (1) UY38480A (es)
WO (1) WO2020106767A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2025046488A1 (en) * 2023-08-30 2025-03-06 BT DE Investments Inc. Synthetic cannabinoids for use in therapy and for enhancement of wellbeing

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385365A (en) 1943-02-17 1945-09-25 Wisconsin Alumni Res Found Salicylic acid compounds for safer therapeutic use
US3939259A (en) 1974-05-24 1976-02-17 Anthony Pescetti Coating composition and therapeutic preparation incorporating same
DE2537232B2 (de) 1974-08-22 1976-07-01 Spritz- und formmasse
US4374082A (en) 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
DE3776116D1 (de) 1986-12-30 1992-02-27 American Cyanamid Co Zusammensetzung die ein polycarbophil enthaelt.
US4758597A (en) 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4902513A (en) 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament
US5965162A (en) 1993-09-10 1999-10-12 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
WO1998008490A1 (en) 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
EP1049474A4 (en) 1998-11-24 2004-12-29 Univ Connecticut CANNABIMIMETIC LIPID AMIDES FOR USE AS MEDICINES
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6495177B1 (en) 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
CN100391438C (zh) 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
EP1231273A1 (en) 2001-02-12 2002-08-14 Plant Research International B.V. Terpene synthase/cyclase and olefin synthase and uses thereof
GB2377633A (en) 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
CA2438097C (en) 2001-02-14 2006-04-25 Gw Pharma Limited Cannabinoids pharmaceutical formulations
BR0208984A (pt) 2001-04-18 2004-06-29 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos
IL143318A0 (en) 2001-05-23 2002-04-21 Herbal Synthesis Corp Herbal compositions for the treatment of mucosal lesions
AU2002352974A1 (en) 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
EP1567513A2 (en) 2002-12-04 2005-08-31 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP1694300A4 (en) 2003-12-09 2009-04-29 Pharmasset Inc DOSAGE PROCESS FOR BETA-D-2 ', 3'-DIDEOXY-2', 3'-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
CA2551946A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
IL162636A0 (en) 2004-06-20 2005-11-20 Yissum Res Dev Co Resorcinol derivatives and their use for lowering blood pressure
ZA200703517B (en) 2004-10-22 2008-08-27 Pharmos Corp Orally effective cannabinoid analogs
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
GB0507167D0 (en) 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
JP5430929B2 (ja) 2005-06-17 2014-03-05 フイルメニツヒ ソシエテ アノニム 新規セスキテルペン合成酵素ならびにその使用方法
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
JP2009514890A (ja) 2005-11-07 2009-04-09 マーティ・ファーマシューティカルズ・インク テトラヒドロカンナビノールの改良された送達
US9265724B2 (en) 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
AR059035A1 (es) 2006-01-16 2008-03-12 Syngenta Participations Ag Insecticidas derivados de antranilamida
US20070254911A1 (en) 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008025535A1 (en) 2006-08-30 2008-03-06 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
PL2063861T3 (pl) 2006-09-15 2015-07-31 Echo Pharmaceuticals Bv Jednostka dawkowania do podawania podjęzykowego, podpoliczkowego lub doustnego nierozpuszczalnych w wodzie substancji aktywnych farmaceutycznie
GB0624340D0 (en) 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
WO2008118414A1 (en) 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2008122965A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
US20090155392A1 (en) 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
WO2009100245A1 (en) 2008-02-05 2009-08-13 Emisphere Technologies Inc. Low dose hmg-coa reductase inhibitor with reduced side effects
US20110137040A1 (en) 2008-08-01 2011-06-09 Lange Josephus H M Synthesis of 3,4-diaryl-4,5-dihydro-(h)-pyrazole-1-carboxamidine derivatives
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
CN101439074B (zh) 2008-12-11 2012-06-06 深圳海王药业有限公司 苍术总萜醇提取物及其制备方法和用途
US20100273895A1 (en) 2009-04-28 2010-10-28 Alltranz Inc. Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
TR201815752T4 (tr) 2010-11-25 2018-11-21 Aop Orphan Pharmaceuticals Ag Nabilon ve rastomal metilen beta siklodekstrin içeren hızlı parçalanan bileşimler.
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
DK2760444T3 (da) 2011-09-29 2020-07-27 Thc Pharm Gmbh The Health Concept Cannabinoidcarboxylsyrer, salte af cannabinoidcarboxylsyrer, fremstilling og anvendelse deraf
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
IN2014MN01933A (es) 2012-03-13 2015-07-10 Piramal Entpr Ltd
AU2013257322A1 (en) 2012-05-03 2014-11-20 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising delta9-tetrahydrocannabinol and a method for preparing such an isolate
EP2666461B1 (en) 2012-05-23 2015-07-01 Tergum S.L. Terpene extract for the treatment of hair loss
RU2657749C2 (ru) 2012-09-21 2018-06-15 Интенсити Терапьютикс, Инк Способы лечения рака
US20150273069A1 (en) 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
JP6581509B2 (ja) 2013-02-28 2019-09-25 ティーウィノット テクノロジーズ リミテッド 化合物を合成する化学工学プロセス及び装置
EP2968259B1 (en) 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
KR101612931B1 (ko) 2013-03-15 2016-04-18 한국유나이티드제약 주식회사 1일 1회 투여로 약리학적 임상 효과를 제공하는 모사프리드 서방성 제제
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US9326967B2 (en) 2013-08-22 2016-05-03 Stephen C. Perry Vaporizable cannabinoid compositions
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US9532593B2 (en) 2013-12-26 2017-01-03 John Turner Herbal smoking blend
WO2015118549A1 (en) 2014-02-10 2015-08-13 F&C Licorice Ltd. Encapsulated biologically active agents
CA2845443A1 (en) 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
WO2016205923A1 (en) 2015-06-25 2016-12-29 Compressed Perforated Puck Technologies Inc. Ingestible plant source pill and method
KR102393596B1 (ko) 2016-04-22 2022-05-04 리셉터 홀딩스, 인크. 속효성 식물-계 의약 화합물 및 영양 보충제
IL321113A (en) * 2016-08-17 2025-07-01 Entera Bio Ltd Formulations for oral administration of active agents
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR20190103302A (ko) 2017-01-03 2019-09-04 리셉터 홀딩스, 인크. 의약 화합물 및 영양 보충제
AU2018233582B2 (en) 2017-03-16 2022-04-07 CannTab Therapeutics, Limited Modified release multi-layer tablet cannabinoid formulations
EP3600436A4 (en) 2017-03-23 2020-12-30 Receptor Holdings, Inc. RAPID AND CONTROLLED ADMINISTRATION OF COMPOSITIONS WITH RESTORED SURROUNDING EFFECTS
BR112020006690A2 (pt) 2017-10-05 2020-10-06 Receptor Holdings, Inc. composições à base de plantas com biodisponibilidade aprimorada
AR113749A1 (es) 2017-10-05 2020-06-10 Receptor Holdings Inc Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada

Also Published As

Publication number Publication date
EP3883595A1 (en) 2021-09-29
AU2019385420A1 (en) 2021-07-08
EP3883595A4 (en) 2022-12-14
WO2020106767A1 (en) 2020-05-28
US20210393575A1 (en) 2021-12-23
US12303487B2 (en) 2025-05-20
UY38480A (es) 2020-06-30
CA3120001A1 (en) 2020-05-28
MX2021005807A (es) 2021-07-02
JP7566336B2 (ja) 2024-10-15
JP2022507730A (ja) 2022-01-18
US20250268861A1 (en) 2025-08-28
JP2024178417A (ja) 2024-12-24

Similar Documents

Publication Publication Date Title
AR117118A1 (es) Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides
ES2505615T3 (es) Proceso para fabricar zeolita de tipo MWW de titanio
UY31402A1 (es) "piperazino-dihidrotienopirimidinas sustituidas en heterociclo"
ECSP10010156A (es) Piperidino-dihidrotienopirimidinas sustituidas
GB0305929D0 (en) Organic compounds
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
GT200300219A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
UY30287A1 (es) Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias
BRPI0918033A8 (pt) Metodo para melhorar a saude de um animal nao inseto e nao humano, e, composicao para melhorar a condicao fisica de um animal nao inseto e nao humano
AR059150A1 (es) Activador metabolico y nutricional para las plantas
CO6331428A2 (es) Compuestos que comprenden un grupo ciclobutoxi
SI2890684T1 (en) THE CLOTHING MACHINE AND THEIR USE AS ENCLOSURE INHIBITORS
AR059182A1 (es) Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
MX2024010568A (es) Compuestos terapeuticos, formulaciones y uso de estos.
UY30529A1 (es) Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones
AR076979A1 (es) 2- aminooxazolinas como ligandos de taar1
UY29618A1 (es) " pirazolo(1,5-a) pirimidinas halogenadas, métodos, usos, composiciones e intermedios"
AR047344A1 (es) Regulacion de crecimiento de plantas
BRPI0909824A2 (pt) 2-aminoquinolinas
EP1561820A4 (en) NEW SUBSTANCE FKI-1033 AND METHOD FOR THE PRODUCTION THEREOF
MX9703712A (es) Derivados de 6-metoxi-1h-benzotriazol-5-carboxamida, sus procesos de produccion y las composiciones farmaceuticas que los contienen.
AR070004A1 (es) Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
NI201000066A (es) AMINAS UNIDAS A LOS MODULADORES DE LA y-SECRETASA.
TH188898S (th) อุปกรณ์ดับกลิ่นในอากาศ

Legal Events

Date Code Title Description
FB Suspension of granting procedure